This service is provided by the Biomarkers Core Laboratory.
The Biomarkers Core Laboratory (BCL) offers expert technical assistance with experimental design and Liquid Chromatography Mass Spectrometry (LCMS) assay development for Adsorption, Distribution, Metabolism and Elimination (ADME) and Pharmacokinetic and Pharmacodynamic (PK-PD) studies during all phases of drug development. Examples of previously developed LCMS methods include quantitative assays for Ricolinostat, Ibrutinib, Pralatrexate, Romidepsin (Lymphoma) and LOC14 (Huntington’s disease) in blood, urine and tissue samples of animals and humans. Our services also include quantitative LCMS based assays for small molecule drugs such as Truvada (emtricitabine/Tenofovir) for HIV, contraceptive drugs (Etonogestrel, Levonogestrel, Ulipristal Acetate) and Opioids (pain management). The core is also committed to supporting novel drug development efforts by developing customized and well-validated (according to FDA guidelines) LCMS based assays for quantitation of drugs and their metabolites.
The drug monitoring assays are set up on a LC-MS/MS platform using customized sample preparation protocols and multiple reaction monitoring (MRM) under positive or negative electrospray ionization mode, depending on the chemical characteristics of the compounds. Drug quantitation is based on external reference standards and stable isotope labeled (13C, 2H) internal standards.
Starting in March 2020, we are also providing support for COVID-19 research.
At BCL, Agilent 6410A mass spectrometer coupled with Agilent 1290 Infinity UHPLC serves as a robust platform for pharmacokinetic profiling assays. Agilent 6410 is known to deliver reliable performance, sensitivity and throughput necessary for quantitative applications in ADME/PKPD studies and biomarker validation in clinical research.
The BCL is open Monday – Friday, 9am to 5pm. Samples may be dropped off during these hours and dry ice must be used during transportation.
Eligibility and Requirements
Pharmacokinetic profiling services are available to all researchers at Columbia University and at other academic institutions.
Investigators that are not affiliated with Columbia University will need to complete a service agreement that must be signed by the legal or purchasing departments of both parties. This process takes approximately four weeks to finalize. The requestor’s legal or purchasing department’s service agreement template is typically used, but one can be provided by Columbia if necessary. For more information on service agreements and pricing for non-CU initiated studies, please email the BCL director, Dr. Renu Nandakumar.
The BCL is not Clinical Laboratory Improvement Amendments (CLIA)-certified. The data generated from BCL is to be used for research purposes only and not for clinical and diagnostic applications.
A new protocol submission request must be initiated in iLab for every new project. Samples will not be accepted without an active service request. Additional request details forms must be submitted if more assays or samples need to be added to an existing protocol. Please contact us for the instructions on how to register and submit a service request through iLab.
Please review the BCL’s User Policy and General Sample Submission Guidelines prior to submitting the samples and complete the downloadable sample list template to be delivered along with your samples.
When to Request This Service
We strongly encourage investigators to contact BCL director, Dr. Renu Nandakumar, prior to submitting a new service request. This will facilitate a discussion on the project, scope, feasibility, appropriate analytical strategy and other sample requirements.
A complete list of the mass spectrometry-based assays including drug monitoring assays and associated cost is available on our downloadable price list.
Cite it, Submit it, Share it!
If your research has benefited from one or more Irving Institute resources, please remember to: